期刊文献+

参麦注射液对陈旧性前壁心肌梗死合并心力衰竭患者血清胱抑素C的影响研究 被引量:4

Influence of serum Cystatin-C from patients with old anterior myocardial infarction combined with congestive heart failure treated by Shenmai injecta
下载PDF
导出
摘要 目的通过综合研究参麦(SM)注射液对陈旧性前壁心肌梗死(MI)合并心力衰竭(CHF)患者血清胱抑素C(Cys-C)、脑钠肽(BNP)、尿素氮(BUN)、血肌酐(Cr)的影响,观察SM对MI合并CHF的治疗作用以及肾功能保护作用。方法将50例患者分成两组,对照组采用常规治疗,治疗组加用参麦注射液30mL,每日1次,14d为1个疗程。结果治疗组与对照组治疗前后BNP、Cys-C、BUN、Cr均有所下降(P<0.05),同时,治疗组优于对照组(P<0.05)。结论参麦可有效改善MI合并CHF患者的症状,并且对肾功能有保护作用。 Objective To comprehensively study the influences of the serum cystatin-C (Cys-C), brain natriuretic pep- tide (BNP), blood urea nitrogen (BUN), and creatinine (Cr) from patients with old anterior myocardial infarction (MI) combined with congestive heart failure (CHF) treated by Shenmai (SM) Injecta and observe its curative effect and pro- teetion of renal functions. Methods Fifty patients with old anterior MI combined with CHF were divided into two groups. In the control group, conventional therapy was adopted; while in the treatment group, besides the conventional method, 30 mL SM injecta was additionally used, once a day and each course of treatment lasted for 14 days. Results The indexes like BNP, Cys-C, BUN, Cr before and after treatment in both groups were decreased (P 〈 0.05). Mean- while, the indexes in the treatment group were superior to those in the control group (P 〈 0.05). Conclusion The SM injecta can effectively better symptoms of MI with CHF patients and protect their renal functions.
作者 王翠芬
出处 《中国当代医药》 2013年第12期125-126,共2页 China Modern Medicine
关键词 参麦 陈旧性前壁心肌梗死合并心力衰竭 脑钠肽 血清胱抑素C 尿素氮 血肌酐 Shenmai injecta Old anterior myocardial infarction combined with congestive heart failure Brain natri-uretic peptide (BNP) Cystatin-C (Cys-C) Blood urea nitrogen (BUN) Creatinine (Cr)
  • 相关文献

参考文献8

二级参考文献64

共引文献2628

同被引文献26

  • 1Meyer T, Shih J, Aurigemma G. Heart failure with preserved ejection fraction ( diastolic dysfunction) [ J ]. Ann Intern Med, 2013,158 ( 1 ) : C1 -C5, C5-C16.
  • 2Waheed S, Matsushita K, Sang Y, et al. Combined association of albumi- nuria and cystatin C-based estimated GFR with mortality, coronary heartdisease, and heart failure outcomes: the Atherosclerosis Risk in Com- munities ( ARIC ) Study [ J ]. Am J Kidney Dis,2012,60 (2) :207-216.
  • 3Metra M, Cotter G, Gheorghiade M, et al. The role of the kidney in heart failure[J]. Eur Heart J, 2012,33(17) :2135-2142.
  • 4Horio M, Imai E, Yasuda Y, et al. GFR estimation using standardized se- rum cystatin C in Japan[ J]. Am J Kidney Dis,2013,61 (2) : 197-203.
  • 5Damman K, van der Harst P, Smilde T D, et al. Use of cystatin C lev- els in estimating renal function and prognosis in patients with chronic systolic heart failure[J]. Heart, 2012,98(4) :319-324.
  • 6Ix JH, Shlipak MG, Chertow GM, et al. Cystatin C, left ventricular hy- pertrophy, and diastolic dysfunction : data from the Heart and Soul Study [J]. J Card Fail, 2006,12(8) :601-607.
  • 7Moran A, Katz R, Smith NL,et al. Cystatin C concentration as a predic- tor of systolic and diastolic heart failure [ J ]. J Card Fail, 2008,14 ( 1 ) : 19-26.
  • 8Woitas R. Assessment of renal function with cystatin C[ J]. Dtsch Med Wochenschr, 2010,135(24) :1252-1254.
  • 9Angelidis C, Dcftereos S, Giannopoulos G, et al. Cystatin C: an emer- ging biomarker in cardiovascular disease [ J ]. Curr Top Med Chem, 2013,13(2) :164-179.
  • 10Lee DS, Guna P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute [ J ]. Circulation, 2009,119 (24) : 3070-3077.

引证文献4

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部